SynthesisWorld journal of surgical oncology2026
En bloc versus conventional transurethral resection for non-muscle-invasive bladder cancer: an expanded and updated systematic review and meta-analysis reconciling contemporary evidence on oncological, pathological, and safety outcomes.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathological assessment of morcellated tissue after ERBT: insights from a two-round Delphi survey.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis systematic review and meta-analysis compares oncological outcomes, pathological quality, and safety profiles between en bloc (ERBT) and conventional transurethral resection (cTURBT) for non-muscle-invasive bladder cancer (NMIBC), incorporating the latest evidence from randomized trials and high-quality observational studies.
methodsWe systematically searched PubMed, Embase, Cochrane Library, and Web of Science (up to December, 2024) for studies comparing ERBT and cTURBT outcomes. Methodological quality was assessed using standardized tools, with statistical analysis performed using RevMan 5.3.
resultsOur meta-analysis incorporated 35 studies involving 6,013 patients with NMIBC. The overall methodological quality was high with a low risk of bias in most included trials; however, moderate to substantial heterogeneity was observed for several outcomes, and potential publication bias was detected for certain safety endpoints. The pooled results demonstrated statistically significant advantages for ERBT in reducing tumor recurrence at 12 months (OR = 0.56, 95% CI: 0.33–0.95; p = 0.03) and 24 months (OR = 0.70, 95% CI: 0.53–0.91; p = 0.009), though recurrence rates at 36 months showed no significant difference between techniques (p > 0.05). Similarly, progression risks did not differ significantly between groups at any time point (all p > 0.05). Pathological evaluation revealed superior outcomes with ERBT, including significantly higher detrusor muscle presence in specimens (OR = 2.60, 95% CI: 1.70–3.99; p < 0.0001) and lower residual tumor rates (OR = 0.60, 95% CI: 0.37–0.99; p = 0.05). However, mucosal muscle detection rates were comparable between techniques (p = 0.21). Regarding safety outcomes, ERBT demonstrated significantly lower risks of bladder perforation (OR = 0.36, 95% CI: 0.22–0.59; p < 0.0001), obturator nerve reflex (OR = 0.13, 95% CI: 0.06–0.29; p < 0.00001), and transfusion requirements (OR = 0.17, 95% CI: 0.04–0.80; p = 0.02). Perioperative metrics favored ERBT with shorter catheterization duration (p = 0.002), reduced hospital stay (p = 0.0002), faster resection time (p = 0.009), and better hemoglobin preservation (p = 0.006), while maintaining equivalent overall surgical times (p = 0.15).
conclusionsERBT offers superior short-term oncological control, improved pathological assessment, and enhanced perioperative safety versus cTURBT, supporting its role as a preferred resection technique for NMIBC, despite equivalent long-term outcomes. Clinical implementation should consider individual tumor characteristics and surgeon expertise.
trial registrationCRD420251032096.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.